Healthcare Industry News: La Jolla Pharmaceutical Company
News Release - October 15, 2015
GenomeDx Biosciences Adds Tina Nova and Craig Johnson to Board of DirectorsSAN DIEGO, Oct. 15, 2015 -- (Healthcare Sales & Marketing Network) -- GenomeDx Biosciences, a genomic information company, today announced that Tina Nova, Ph.D., and Craig Johnson have been appointed to its board of directors.
"Tina and Craig each have considerable leadership and expertise that will help launch GenomeDx into its next phase of growth," said Doug Dolgniow, CEO of GenomeDx. "We welcome them to our board of directors as we continue to move toward transforming cancer patient care through the growth of our Decipher Test franchise and innovative programs like the Decipher GRID."
Dr. Nova has been at the forefront of personalized cancer diagnostics for two decades. She co-founded the molecular diagnostics company Genoptix in 2000, and served as President, CEO and Director until its acquisition by Novartis AG in 2011. Prior to that, Dr. Nova co-founded Nanogen Inc., a provider of diagnostic testing, where she served as President and COO. She holds a bachelor's degree in Biological Sciences from the University of California, Irvine, and a doctorate in Biochemistry from the University of California, Riverside.
Mr. Johnson has more than 25 years of experience leading companies and serving in senior financial management roles, primarily in the biotechnology industry. He is currently a director for Mirati Therapeutics, La Jolla Pharmaceutical Company and Heron Therapeutics, and he also served as a director of Ardea Biosciences until its acquisition by AstraZeneca in 2012. He previously served as Chief Financial Officer at NovaDel Pharma, TorreyPines Therapeutics and MitoKor, and he began his career with Price Waterhouse. Mr. Johnson received a bachelor's degree in accounting from the University of Michigan-Dearborn.
About Decipher® Prostate Cancer Classifier
Decipher® is a genomic test that provides an assessment of tumor aggressiveness and is used by urologists and radiation oncologists to determine who to treat and how to treat them in order to offer the most effective and least harmful course of therapy. Decipher offers valuable insight that is distinct from clinical measures of risk including PSA and Gleason score. Studies of thousands of patients from leading cancer centers, published in more than 20 peer-reviewed journals, demonstrate that Decipher can accurately predict metastatic disease, identify patients most likely to benefit from therapeutic intervention, and lead to significant cost-savings for healthcare systems by reducing unnecessary procedures. Decipher is covered by Medicare and multiple private insurance plans in the US representing over 190 million covered lives. Learn more at www.DecipherTest.com
About Decipher GRIDTM
The Decipher Genomic Resource Information Database (Decipher GRID™) is the world's largest clinically-annotated genomic expression database in urologic cancer created to enable improvements to precision medicine in patient care. GRID unifies a patient's whole genome data with clinical outcomes from thousands of patients evaluated with Decipher®, providing unprecedented data sharing capabilities. Ultimately, GRID will use patient tumor genomic information to better match an individual to a targeted therapy with the highest likelihood of providing a benefit. The Decipher GRID program is rapidly expanding as major cancer centers partner with GenomeDx to access the database to advance their understanding of urologic cancers through the analysis of large amounts of genomic data. Learn more at www.DecipherGRID.com
About GenomeDx Biosciences
GenomeDx Biosciences is a genomic information company changing the landscape of urologic cancer patient care with innovative genomic solutions that empower physicians and patients to make more informed decisions about patient treatment. Using advanced cloud-based bioinformatics to mine vast amounts of genomic data, the company develops and commercializes proprietary clinical tests that provide actionable information to answer key clinical questions in patient management. GenomeDx's Decipher® is a genomic test that provides an assessment of tumor aggressiveness and is used by urologists and radiation oncologists to determine who to treat and how to treat them in order to offer the most effective and least harmful course of therapy. In partnership with leading medical centers, GenomeDx is building Decipher GRIDTM, the world's largest clinically-annotated genomic expression database in urologic cancer created to enable improvements to precision medicine in patient care. GenomeDx is based in San Diego and Vancouver, British Columbia. Learn more at www.GenomeDx.com
Source: GenomeDx Biosciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.